


|                      |   |
|----------------------|---|
| <b>Name:</b>         |  |
| <b>Enrolment No:</b> |   |

**UNIVERSITY OF PETROLEUM AND ENERGY STUDIES**  
**End Semester Examination, December 2022**

|  |                          |
|--|--------------------------|
| <b>Course: Ethics in Clinical Research</b>                       | <b>Semester : III</b>    |
| <b>Program: Integrated (B. Sc.) - (M. Sc.) Clinical Research</b> | <b>Duration: 3 Hours</b> |
| <b>Course Code: HSCR2016</b>                                     | <b>Max. Marks: 100</b>   |

**Instructions:**

| S. No. | Section A<br><br>Short answer questions/ MCQ/T&F<br>(20Qx1.5M= 30 Marks)   | Marks | COs |
|--------|--|-------|-----|
| Q 1    | What is an “investigational new drug”?   | 1.5   | CO1 |
| Q 2    | Application for permission to import of drugs comes under the rule<br>a) 122A<br>b) 122B<br>c) 122DA<br>d) 122E  | 1.5   | CO2 |
| Q 3    | What should a narrative of ADR consist of?   | 1.5   | CO1 |
| Q 4    | What are the objectives of obtaining IEC/IRB review of the protocol?   | 1.5   | CO3 |
| Q 5    | Define orphan drugs?   | 1.5   | CO1 |
| Q 6    | Which document created in 1964 forms the basis of ethical considerations in clinical research?<br>a) Declaration of Geneva<br>b) Declaration of Helsinki<br>c) Declaration of Belfast<br>d) All of the above | 1.5   | CO1 |
| Q 7    | What is pharmacovigilance?   | 1.5   | CO1 |
| Q 8    | Define cohort study?   | 1.5   | CO1 |
| Q 9    | What is the difference between monitoring and auditing?  | 1.5   | CO3 |
| Q 10   | Define the term “placebo”?   | 1.5   | CO1 |
| Q 11   | What do you understand by “confidentiality” in clinical research?  | 1.5   | CO3 |
| Q 12   | What is the purpose of Good Clinical Practice (GCP)  | 1.5   | CO3 |
| Q 13   | What is a protocol?  | 1.5   | CO1 |
| Q 14   | What is observational research? Give an example.   | 1.5   | CO1 |
| Q 15   | How the quality systems are implemented within GCP?  | 1.5   | CO3 |
| Q 16   | 122DA rule of Drug and cosmetic acts, 1945 deals with<br>a) Permission to import/manufacture Fixed Dose Concentration  | 1.5   | CO2 |

|  |  |            |                             |
|--|--|------------|-----------------------------|
|  | b) Permission to conduct Clinical Trials<br>c) Clinical Trial Definition<br>d) New Drug Definition   |            |                             |
| <b>Q 17</b>                                  | Enlist three cardinal principles of Belmont report?  | <b>1.5</b> | <b>CO3</b>                  |
| <b>Q 18</b>                                  | What is a AE and how is it different from ADR?   | <b>1.5</b> | <b>CO1</b>                  |
| <b>Q 19</b>                                  | What is source document?   | <b>1.5</b> | <b>CO1</b>                  |
| <b>Q 20</b>                                  | Define double blinding?  | <b>1.5</b> | <b>CO1</b>                  |
| <b>Section B</b><br><b>(4Qx5M=20 Marks)</b>  |  |            |                             |
| <b>Q 1</b>                                   | Discuss the toxicity study data required to be submitted for conduct of clinical trial of new drug or investigational new drug?                            | <b>5</b>   | <b>CO5</b>                  |
| <b>Q 2</b>                                   | Brefily describe the EMA guidance for pharmacoepidemiologic assessment ?   | <b>5</b>   | <b>CO4</b>                  |
| <b>Q 3</b>                                   | Highlight the ICMR Ethical guidelines for biomedical research.   | <b>5</b>   | <b>CO2</b>                  |
| <b>Q 4</b>                                   | Discuss the ethical aspects of conducting drug trials in pregnant women.   | <b>5</b>   | <b>CO5</b>                  |
| <b>Section C</b><br><b>(2Qx15M=30 Marks)</b> |  |            |                             |
| <b>Q 1</b>                                   | Write a short note on following:<br>a) Legal and ethical components of informed consent<br>b) Tuskegee Syphilis Study<br>c) NDA 505(b) (2) of the FD&C Act | <b>15</b>  | <b>CO1,<br/>CO3<br/>CO4</b> |
| <b>Q 2</b>                                   | Describe the schedule Y for clinical trial regulation in India?  | <b>15</b>  | <b>CO2</b>                  |
| <b>Section D</b><br><b>(2Qx10M=20 Marks)</b> |  |            |                             |
| <b>Q 1</b>                                   | What is CDSCO? Explain the structure, role and responsibilities of CDSCO.  | <b>10</b>  | <b>CO2</b>                  |
| <b>Q 2</b>                                   | Discuss the FDA Safety Reporting Requirements for INDs and BA/BE Studies?  | <b>10</b>  | <b>CO4</b>                  |